¹⁸F-fluorodeoxyglucose positron emission tomography-computed tomography as a prognostic marker of imatinib-resistant gastrointestinal stromal tumors.

IF 1.6 4区医学 Q2 SURGERY

Surgery Today Pub Date : 2025-09-01 Epub Date: 2025-03-28 DOI:10.1007/s00595-025-03029-7

Kota Kawabata, Tsuyoshi Takahashi, Toshirou Nishida, Yukinori Kurokawa, Kazuyoshi Yamamoto, Takuro Saito, Kota Momose, Kotaro Yamashita, Koji Tanaka, Tomoki Makino, Ryohei Kawabata, Atsushi Takeno, Kiyokazu Nakajima, Hidetoshi Eguchi, Yuichiro Doki

{"title":"18F-fluorodeoxyglucose positron emission tomography-computed tomography as a prognostic marker of imatinib-resistant gastrointestinal stromal tumors.","authors":"Kota Kawabata, Tsuyoshi Takahashi, Toshirou Nishida, Yukinori Kurokawa, Kazuyoshi Yamamoto, Takuro Saito, Kota Momose, Kotaro Yamashita, Koji Tanaka, Tomoki Makino, Ryohei Kawabata, Atsushi Takeno, Kiyokazu Nakajima, Hidetoshi Eguchi, Yuichiro Doki","doi":"10.1007/s00595-025-03029-7","DOIUrl":null,"url":null,"abstract":"Purpose: Unresectable or metastatic GISTs often develop resistance to imatinib, but the effectiveness of other drugs is limited. Thus, surgical treatment can be considered, especially for partial resistance. FDG-PET/CT is used for the diagnosis and evaluation of GISTs. We conducted this study to establish whether FDG-PET/CT findings could guide treatment decisions and predict the prognosis of patients with imatinib-resistant GISTs.Methods: We analyzed data retrospectively from 45 patients with imatinib-resistant GISTs that were assessed via FDG-PET/CT at our institution between 2003 and 2021. The patients were classified as having low (n = 18) or high (n = 27) SUVmax, with a cutoff value of 5.0.Results: The overall survival (OS) of the patients with low SUVmax after the diagnosis of imatinib resistance was significantly prolonged. Multivariate analysis identified SUVmax as an independent poor prognostic factor. In 23 patients with resected imatinib-resistant lesions, a close correlation was found between the SUVmax by preoperative FDG-PET/CT and the mitotic rate. A higher SUVmax was associated with a higher mitotic rate. Patients with a low SUVmax (n = 11) had significantly longer postoperative imatinib failure-free survival than those with a high SUVmax (n = 12).Conclusions: FDG-PET/CT assessment and diagnosis might reveal the pathological grades of imatinib-resistant GISTs and act as a prognostic marker.","PeriodicalId":22163,"journal":{"name":"Surgery Today","volume":" ","pages":"1295-1302"},"PeriodicalIF":1.6000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgery Today","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00595-025-03029-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Unresectable or metastatic GISTs often develop resistance to imatinib, but the effectiveness of other drugs is limited. Thus, surgical treatment can be considered, especially for partial resistance. FDG-PET/CT is used for the diagnosis and evaluation of GISTs. We conducted this study to establish whether FDG-PET/CT findings could guide treatment decisions and predict the prognosis of patients with imatinib-resistant GISTs.

Methods: We analyzed data retrospectively from 45 patients with imatinib-resistant GISTs that were assessed via FDG-PET/CT at our institution between 2003 and 2021. The patients were classified as having low (n = 18) or high (n = 27) SUV_max, with a cutoff value of 5.0.

Results: The overall survival (OS) of the patients with low SUV_max after the diagnosis of imatinib resistance was significantly prolonged. Multivariate analysis identified SUV_max as an independent poor prognostic factor. In 23 patients with resected imatinib-resistant lesions, a close correlation was found between the SUV_max by preoperative FDG-PET/CT and the mitotic rate. A higher SUV_max was associated with a higher mitotic rate. Patients with a low SUV_max (n = 11) had significantly longer postoperative imatinib failure-free survival than those with a high SUV_max (n = 12).

Conclusions: FDG-PET/CT assessment and diagnosis might reveal the pathological grades of imatinib-resistant GISTs and act as a prognostic marker.

查看原文本刊更多论文

18f -氟脱氧葡萄糖正电子发射断层扫描-计算机断层扫描作为伊马替尼耐药胃肠道间质肿瘤的预后标志物。

目的：不可切除或转移性胃肠道间质瘤常对伊马替尼产生耐药性，但其他药物的疗效有限。因此，可以考虑手术治疗，特别是对于部分抵抗。FDG-PET/CT用于胃肠道间质瘤的诊断和评价。我们进行这项研究是为了确定FDG-PET/CT的表现是否可以指导治疗决策和预测伊马替尼耐药gist患者的预后。方法：我们回顾性分析了2003年至2021年在我院通过FDG-PET/CT评估的45例伊马替尼耐药gist患者的数据。将患者分为低SUVmax （n = 18）和高SUVmax (n = 27)，临界值为5.0。结果：低SUVmax患者诊断为伊马替尼耐药后总生存期（OS）明显延长。多变量分析确定SUVmax是一个独立的不良预后因素。在23例切除的伊马替尼耐药病变患者中，术前FDG-PET/CT的SUVmax与有丝分裂率密切相关。较高的SUVmax与较高的有丝分裂率相关。低SUVmax患者（n = 11）术后伊马替尼无衰竭生存期明显长于高SUVmax患者（n = 12）。结论：FDG-PET/CT评估和诊断可揭示伊马替尼耐药gist的病理分级，并可作为预后指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Surgery Today 医学-外科

CiteScore

4.90

自引率

4.00%

发文量

208

审稿时长

1 months

期刊介绍： Surgery Today is the official journal of the Japan Surgical Society. The main purpose of the journal is to provide a place for the publication of high-quality papers documenting recent advances and new developments in all fields of surgery, both clinical and experimental. The journal welcomes original papers, review articles, and short communications, as well as short technical reports("How to do it"). The "How to do it" section will includes short articles on methods or techniques recommended for practical surgery. Papers submitted to the journal are reviewed by an international editorial board. Field of interest: All fields of surgery.